Smartleaf Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Smartleaf Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.86K	Sell	726 -229	-24%	-$1.78K	﹤0.01%	2503
2025 Q4	$7.32K	Buy	955 +17	+2%	+$123	﹤0.01%	2531
2025 Q3	$7.08K	Buy	938 +647	+222%	+$5.39K	﹤0.01%	2249
2025 Q2	$2.72K	Buy	291 +203	+231%	+$1.89K	﹤0.01%	2245
2025 Q1	$691	Sell	88 -452	-84%	-$3.65K	﹤0.01%	2642
2024 Q4	$4.07K	Buy	540 +360	+200%	+$2.73K	﹤0.01%	2324
2024 Q3	$1.37K	Buy	+180	New	+$1.37K	﹤0.01%	2586

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Smartleaf Asset Management's BCRX Position: Q1 2026 in Review

Smartleaf Asset Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 24% in Q1 2026, selling an estimated $1.78K and leaving 726 shares worth $6.86K. The position accounts for ﹤0.01% of the portfolio, ranked #2503.

Smartleaf Asset Management first reported a position in BCRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $7.32K in Q4 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Smartleaf Asset Management held 726 shares of BioCryst Pharmaceuticals worth $6.86K as of Q1 2026.
Smartleaf Asset Management sold 229 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $1.78K.
BioCryst Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2503 holding.
Smartleaf Asset Management first reported a position in BioCryst Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
Smartleaf Asset Management's BioCryst Pharmaceuticals position peaked at $7.32K in Q4 2025.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.